{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (2026Q4)",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.52 vs. cons $1.51",
      "confidence": "HIGH"
    },
    {
      "kpi": "Revenue (2026Q4)",
      "prediction": "IN-LINE",
      "answer": "pred ~$21.95B vs. cons $21.90B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "U.S. local case growth (2026Q4)",
      "prediction": "BEAT",
      "answer": "pred ~2.8% vs. cons 2.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$4.88 vs. cons $5.01 (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue guidance",
      "prediction": "LOWER",
      "answer": "guide ~$88.0B vs. cons $88.5B (FY2027)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A largely in-line quarter and local-volume beat are outweighed by FY2027 guidance below consensus; the ~$0.13 EPS and ~$0.5B revenue shortfalls imply negative out-period revisions that continue after day 1.",
  "day5_confidence": "MEDIUM"
}